Cancer NetworkOriginal article
<![CDATA[PERSEUS Trial Shows Daratumumab Regimen Deepens Responses in NDMM]]>
Phase 3positivedaratumumabPositive
AI Analysis
Summary
The Phase 3 PERSEUS trial of daratumumab-based regimen shows no new safety signals after 3 additional years of follow-up, with deepened responses in newly diagnosed multiple myeloma patients.
Clinical Trial Data
Phase
3
Outcome Details
No new safety signals observed after additional 3 years of follow-up; deepened responses
Importance:6/10
Sentiment:
0.70
daratumumabmultiple myelomaPERSEUSPhase 3safetyfollow-up data
Read the original article
Published by Cancer Network on September 26, 2026 5:00 PM